Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Abbott’s Stent Wins U.S. Approval for Treating Clots in Legs

Abbott Laboratories’ Absolute Pro stent won U.S. Food and Drug Administration approval to treat patients with clogged arteries leading to the legs.

The condition, known as peripheral artery disease, develops when a blockage or narrowing in the vessel reduces the blood supply to the legs, causing chronic pain and trouble walking. The stent is threaded into the blockage in the iliac artery that runs from the hip down the leg, and expanded to clear a path for blood to resume flowing.

Between 8 million and 12 million American are affected by the condition, which also affects blood flow to the head, arms and kidneys, said the Peripheral Arterial Disease Coalition in Lakewood, Colorado. Patients who used Absolute Pro had significantly fewer deaths, heart attacks or repeated procedures than expected based on previous trials using older stents, the Abbott Park, Illinois-based company said in a statement today.

“Iliac artery disease greatly impacts patients’ overall quality of life,” said study investigator Tony Das, director of peripheral vascular interventions at Presbyterian Heart Institute in Dallas, in a statement. “U.S. physicians now have an additional option that is proven safe and effective to treat many patients with this debilitating disease.”

Abbott fell less than 1 percent to $56.26 at the close of New York trading. The shares rose 16 percent in the past 12 months.

Peripheral vascular devices, including stents, angioplasty balloons and synthetic grafts, generated $4.3 billion in global revenue 2010 and may earn $5.6 billion in 2014, according to Technavio, a market research firm in Elmhurst, Illinois.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.